PA
RLAY icon

Parallel Advisors’s Relay Therapeutics RLAY Stock Holding History

Parallel Advisors’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.4K Buy
1,253
+16
+1% +$232 ﹤0.01% 2549
2026
Q1 		$12.3K Buy
1,237
+48
+4% +$429 ﹤0.01% 2657
2025
Q4 		$10.1K Buy
1,189
+15
+1% +$107 ﹤0.01% 2600
2025
Q3 		$6.13K Hold
1,174
– – ﹤0.01% 2708
2025
Q2 		$4.06K Buy
1,174
+1,100
+1,486% +$3.27K ﹤0.01% 2812
2025
Q1 		$194 Buy
+74
New +$290 ﹤0.01% 3385
2024
Q3 		– Sell
-14
Closed -$91 – 3461
2024
Q2 		$91 Hold
14
– – ﹤0.01% 3254
2024
Q1 		$116 Hold
14
– – ﹤0.01% 3202
2023
Q4 		$154 Sell
14
-81
-85% -$684 ﹤0.01% 3197
2023
Q3 		$799 Hold
95
– – ﹤0.01% 3015
2023
Q2 		$1.19K Buy
+95
New +$1.18K ﹤0.01% 2886
2023
Q1 		– Sell
-12
Closed -$179 – 3488
2022
Q4 		$179 Hold
12
– – ﹤0.01% 3210
2022
Q3 		$0 Hold
12
– – ﹤0.01% 3434
2022
Q2 		$0 Buy
+12
New +$257 ﹤0.01% 3295
2022
Q1 		– Sell
-71
Closed -$2K – 3225
2021
Q4 		$2K Buy
+71
New +$2.24K ﹤0.01% 2747

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Parallel Advisors's RLAY Position: Q2 2026 in Review

Parallel Advisors increased its Relay Therapeutics (RLAY) stake by 1.3% in Q2 2026, buying an estimated $232 and bringing the position to 1,253 shares worth $23.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2549.

Parallel Advisors first reported a position in RLAY in Q4 2021 and has held it in 15 quarters since. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Parallel Advisors held 1,253 shares of Relay Therapeutics worth $23.4K as of Q2 2026.
  • Parallel Advisors bought 16 Relay Therapeutics shares in Q2 2026, an estimated $232.
  • Relay Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #2549 holding.
  • Parallel Advisors first reported a position in Relay Therapeutics in Q4 2021 and has held it in 15 quarters since.
  • 259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.